Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)

Exclusion Criteria

• •Patients with any medical condition or illness that, in the opinion of the investigator, could interfere with the study results and/or affect the patients' ability to participate or complete the study.
• •History of clinically significant heart disease (ejection fraction \<40% \[normal range 50-70%\], heart failure defined as New York Heart Association \[NYHA\] Class \> 2; clinically significant congenital or acquired valvular disease; symptomatic coronary artery disease such as myocardial infarction or angina, history of unstable arrhythmias, history of atrial fibrillation).
• •Decreased renal function (estimated glomerular filtration rate \<45 mL/min/1.73 m2, calculated using the CKD-EPI formula) at screening.
• •Alcohol consumption exceeding 30 g/day in men or 20 g/day in women.
• •Patients with significant impairment of liver function in the selection analysis defined as repeated values of AST, ALT, and bilirubin \> 3 times the upper limit of normal.
• •Positive for hepatitis B surface antigen or hepatitis C antibodies.
• •Patients with hepatocellular carcinoma.
• •Patients with liver cirrhosis (Fibroscan® \> 18, compatible biopsy, or those who have experienced decompensations of cirrhosis).
• •Patients diagnosed with human immunodeficiency virus (HIV).
• •Patients with hypersensitivity or a history of severe allergies to NAM or excipients used in the preparation of capsules (NAM and placebo).
• •Patients with iodinated contrast allergy.
• •History or evidence of an autoimmune disorder considered clinically significant by the investigator or requiring systemic, chronic use of systemic corticosteroids or other immunosuppressants.
• •Patients on treatment with hepatotoxic drugs (amiodarone, immunosuppressants, ART, antituberculosis drugs, corticosteroids, etc.).
• •Patients consuming narcotic and psychotropic substances with hepatotoxic effects.
• •Individuals with incapacitating diseases or cognitive impairment.
• •Institutionalized patients or those without a fixed address.
• •Principal investigator's discretion in case of indications of low adherence to the trial or follow-up visits.
• •Individuals with a life expectancy of less than 12 months.
• •Patients participating in another interventional clinical trial, excluding observational/natural history studies, at the start of the study or within the last 30 days before the start of the study.
• •Previous use of vitamin B3 (NAM), with abstinence required for at least 3 months before screening.
• •Pregnant women as determined by a positive high-sensitivity serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent units of hCG) within 24 hours prior to screening, dosing, or completion of the study. Women of childbearing potential (WOCBP) will undergo a pregnancy test (serum or urine) 24 hours prior to screening, dosing, or completion of the study. Such participants must use a highly effective contraceptive method, such as combined hormonal contraceptives or intrauterine device (IUD), in accordance with the Clinical Trial Facilitation Group, throughout the entire study.
• •Breastfeeding women.
• •Patients undergoing treatment/supplementation with vitamin E.
• •Patients receiving probiotics.
• •Patients on the waiting list for bariatric surgery in the next 12 months.
• •Patients undergoing treatment with drugs that may have an effect on the progression of liver disease.
• •Drugs for the treatment of T2DM with effects on NAFLD (GLP-1 analogs, thiazolidinediones such as pioglitazone) initiated within 6 months before the study start.
• •Drugs for the treatment of T2DM with effects on intestinal microbiota (metformin, α-GI inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) initiated within 6 months before the study start.
• •Patients who do not sign the informed consent.
• •Patients with contraindications to the contrast agent to be used in imaging tests.